Phaseline

Companies › Celyad Oncology

Celyad Oncology: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Feb 2035.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CYAD-02
CAR-T cell therapy targeting CLEC12A
CLEC12APhase 1Acute Myeloid LeukemiaFeb 2035
CYAD-101
Allogeneic NKG2D-based chimeric antigen receptor T-cell therapy
NKG2DPhase 1Unresectable Metastatic Colorectal CancerFeb 2036
CYAD-211
Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
BCMAPhase 1Relapse/Refractory Multiple MyelomaFeb 2037

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04167696CYAD-02Phase 1Acute Myeloid LeukemiaOncologyFeb 2035
NCT03692429CYAD-101Phase 1Unresectable Metastatic Colorectal CancerOncologyFeb 2036
NCT04613557CYAD-211Phase 1Relapse/Refractory Multiple MyelomaOncologyFeb 2037
NCT04991948CYAD-101Phase 1Unresectable Metastatic Colorectal CancerOncologyMay 2038

Targets

CLEC12A (1) NKG2D (1) BCMA (1)

Companies with the same targets

iCell Gene Therapeutics AbbVie Chongqing Precision Biotech ARCE Therapeutics CytoMed Therapeutics Pte Poseida Therapeutics Regeneron Pharmaceuticals Johnson & Johnson (Janssen) AstraZeneca Lakefront Biotherapeutics West

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.